Latest Breaking News On - Program highlights milestones - Page 1 : comparemela.com

Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Philip astley sparkeChris brinzeyArleen goldenbergReplimune group incSecurities exchangeInternational society for melanoma research congress onDrug administrationSociety for immunotherapy of cancerExchange commissionProgram highlights milestonesReports fiscal third quarterProvides corporateAnnual meetingAnnual international societyMelanoma research congressSecurities act

Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update

The Company plans to hold a conference call in early December to provide a comprehensive RP1 skin cancer program update including:

Chris brinzeyBristol myers squibbPhilip astley sparkeArleen goldenbergProgram highlights milestonesSociety for immunotherapy of cancerSecurities exchangeReplimune group incInternational society for melanoma research congress onExchange commissionBiologics license applicationAnnual meetingPlenary sessionAnnual international societyMelanoma research congressEmily hill

Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update

Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesInquiriesarleen goldenbergreplimuneVelekar peeples dyerChris brinzeywestwickeBristol myers squibbPhilip astley sparkeReplimune group incCompany board of directorsExchange commissionProgram highlights milestonesGlobal regulatory group at baker mckenzieAmerican transplant congressAmerican society of clinical oncologySecurities exchangeBiologics license applicationClinical trial collaboration

Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update

18.05.2023 - Topline data disclosure from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo (cemiplimab-rwlc) in cutaneous squamous cell carcinoma (CSCC) on track for Q3 2023 and Biologics License Application (BLA) submission on track .

United statesArleen goldenbergBristol myers squibbChris brinzeyJean franchiPhilip astley sparkeAndrew schwendenmanProgram highlights milestonesAmerican transplant congressExchange commissionSecurities exchangeCorporate communicationsReplimune group incVice presidentChief accountingSecurities act